Data and analytics company, GlobalData, has revealed that biosimilars to Humira will have significant uptake across Europe this year as a result of 10–20% lower prices compared with the originator brand.
Along (bio)similar lines
This trend is set to be further facilitated by the quotas that healthcare authorities have put in place for biosimilar prescription, one of the highest coming from the NHS, which is recommending that 90% of new patients and 80% of patients currently receiving therapy be prescribed a lower cost biologic (or biosimilar) within 12 months of its launch.